Durvalumab (9) – Imfinzi®

Non-small cell lung cancer, EGFR/ALK-negative, neoadjuvant/adjuvant therapy, in combination with platinum-based chemotherapy

Characteristics

Start date 01.08.2025 – Marketing authorisation: 31.03.2025
Resolution 22.01.2026
INN Durvalumab
Brand name Imfinzi®
Pharm. company AstraZeneca GmbH
G-BA Procedure ID D-1225
ATC code L01FF03 PD-1/PDL-1 inhibitors (L01FF)
ICD-10 codes (AIS) C34.0Malignant neoplasm of carina, C34.1Malignant neoplasm of upper lobe, bronchus or lung, C34.2Malignant neoplasm of middle lobe, bronchus or lung, C34.3Malignant neoplasm of lower lobe, bronchus or lung, C34.8Malignant neoplasm of overlapping sites of bronchus and lung, C34.9Malignant neoplasm of unspecified part of bronchus or lung
Alpha-ID codes (AIS) I111155Carcinoma of the upper lobe bronchus, I116693Non-small cell lung cancer, I24595Carcinoma of the main bronchus, I30015Lung carcinoma of the middle lobe, I30021Lung carcinoma of the lower lobe, I30022Malignant neoplasm of the bronchi and lungs, overlapping several sub-areas
Therapeutic area Oncological diseases
Reason for procedure New therapeutic indication

Therapeutic indication of the resolution

Imfinzi, in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by Imfinzi as monotherapy for adjuvant treatment, is indicated for adults with resectable NSCLC at high risk of recurrence and without EGFR mutations or ALK translocations.

Subpopulation Indication Comparator
Erwachsene mit resezierbarem NSCLC mit hohem Rezidivrisiko und ohne EGFR-Mutationen oder ALK-Translokationen; neoadjuvante und adjuvante Therapie

Studies and Results

  • Clinical trials
    • The AEGEAN trial is an ongoing, double-blind, randomised Phase IIItrial in which durvalumab in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by durvalumab as monotherapy for adjuvant treatment (intervention arm), was compared with placebo in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by placebo after surgery (control arm).
    • The KEYNOTE 671 trial is an ongoing, double-blind, randomised Phase IIItrial in which pembrolizumab in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by pembrolizumab as monotherapy for adjuvant treatment (intervention arm), was compared with placebo in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by placebo after surgery (comparison arm).

Adults with resectable NSCLC at high risk of recurrence and without EGFR mutations or ALK translocations; neoadjuvant and adjuvant therapy

  • An additional benefit is not proven.
  • In the absence of direct comparative studies, the pharmaceutical manufacturer relies on an adjusted indirect comparison based on the procedure developed by Bucher et al. to demonstrate additional benefit.
  • Consequently, the adjusted indirect comparison submitted is assessed as generally unsuitable for drawing conclusions regarding additional benefit.
  • Consequently, taken as a whole, there are no data available that would allow an assessment of additional benefit.
  • Conclusion
    • With regard to the similarity between the AEGEAN and KEYNOTE 671 studies, and the patient population used for the adjusted indirect comparison, significant uncertainties remain concerning the proportion of patients with an EGFR mutation or ALK translocation.
    • The results of the adjusted indirect comparison set out in the pharmaceutical manufacturer’s dossier show no statistically significant differences in the endpoints of overall survival, event-free survival and adverse events.
    • Consequently, the adjusted indirect comparison submitted is, on the whole, assessed as unsuitable for drawing conclusions regarding additional benefit. The pharmaceutical manufacturer itself does not infer any additional benefit from these results.

Courtesy translation only, please refer to the German original.

Associated procedures

Durvalumab (12) Imfinzi® AstraZeneca GmbH Oncological diseases Adenocarcinoma of the stomach or the gastro-oesophageal junction; neoadjuvant and adjuvant combination with FLOT chemotherapy followed by adjuvant monotherapy n.d. active procedure
Durvalumab (11) Imfinzi® AstraZeneca GmbH Oncological diseases Muscle-invasive bladder cancer (MIBC), neoadjuvant/adjuvant therapy following cystectomy, in combination with gemcitabine and cisplatin 4,310–5,730 100% Indication of minor additional benefit
Durvalumab (10) Imfinzi® AstraZeneca GmbH Oncological diseases Non-advanced small cell lung cancer, following platinum-based chemoradiotherapy, monotherapy 670–1,750 100% Indication of considerable additional benefit
Durvalumab (9) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung cancer, EGFR/ALK-negative, neoadjuvant/adjuvant therapy, in combination with platinum-based chemotherapy 4,540–4,660 100% additional benefit not proven
Durvalumab (7) Imfinzi® AstraZeneca GmbH Oncological diseases Primarily advanced or relapsed endometrial cancer, first-line therapy, combination with carboplatin and paclitaxel; maintenance therapy 380–1,520 100% additional benefit not proven
Durvalumab (8) Imfinzi® AstraZeneca GmbH Oncological diseases Primarily advanced or recurrent endometrial cancer, combination with carboplatin and paclitaxel; maintenance therapy, combination with olaparib 990–1,810 50% Indication of considerable additional benefit
Durvalumab (6) Imfinzi® AstraZeneca GmbH Oncological diseases Hepatocellular carcinoma, first-line, monotherapy 1,900–5,470 100% additional benefit not proven
Durvalumab (3) Imfinzi® AstraZeneca GmbH Oncological diseases Biliary tumors, first-line, combination with gemcitabine and cisplatin 1,800 100% Indication of minor additional benefit
Durvalumab (4) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung cancer, EGFR/ALK-negative, first-line, combination with tremelimumab and platinum-based chemotherapy 14,470–24,660 100% additional benefit not proven
Durvalumab (5) Imfinzi® AstraZeneca GmbH Oncological diseases Hepatocellular carcinoma, first-line, combination with tremelimumab 1,900–5,470 100% additional benefit not proven
Durvalumab (2) Imfinzi® AstraZeneca GmbH Oncological diseases Small cell lung cancer (SCLC), first-line, combination with etoposide and either carboplatin or cisplatin 3,210–6,130 100% Hint for minor additional benefit
Durvalumab (1) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung carcinoma (NSCLC), maintenance therapy 1,600–1,800 100% Hint for considerable additional benefit


<< List of all resolutions